Avadel Pharmaceuticals Stock Forecast, Price & News

-0.07 (-0.87 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume161,786 shs
Average Volume374,920 shs
Market Capitalization$467.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Avadel Pharmaceuticals logo

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.87 out of 5 stars

Medical Sector

693rd out of 1,309 stocks

Pharmaceutical Preparations Industry

346th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

Is Avadel Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Avadel Pharmaceuticals?

Wall Street analysts have given Avadel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avadel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Avadel Pharmaceuticals

How can I listen to Avadel Pharmaceuticals' earnings call?

Avadel Pharmaceuticals will be holding an earnings conference call on Monday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Sunday, May, 9th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09.
View Avadel Pharmaceuticals' earnings history

How has Avadel Pharmaceuticals' stock been impacted by Coronavirus?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVDL stock has increased by 0.1% and is now trading at $8.00.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AVDL?

4 equities research analysts have issued 12-month price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $17.00 to $22.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $19.50 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:
  • Mr. Gregory J. Divis Jr., CEO & Director (Age 54, Pay $897k)
  • Mr. Thomas S. McHugh, Sr. VP & CFO (Age 56, Pay $581.2k)
  • Dr. Jordan S. Dubow M.D., Consultant (Age 43, Pay $727.93k)
  • Mr. Gregory J. Davis, VP of Corp. and Bus. Devel. (Age 56)
  • Mr. Mark W. Elrod, VP of Sales
  • Ms. Angie Woods, VP of People & Culture
  • Mr. Christian Kalita Pharm.D, Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan, VP of Sales & Marketing and Head of Commercial Operations (Age 56)
  • Dr. Jason M. Vaughn, Sr. VP of Technical Operations
  • Mr. Richard Kim, Chief Commercial Officer (Age 52)

Who are some of Avadel Pharmaceuticals' key competitors?

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Asymmetry Capital Management L.P. (0.68%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends for Avadel Pharmaceuticals

Which major investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P..
View insider buying and selling activity for Avadel Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $8.00.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals has a market capitalization of $467.90 million and generates $22.33 million in revenue each year. The company earns $7.03 million in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals employs 32 workers across the globe.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is

Where are Avadel Pharmaceuticals' headquarters?

Avadel Pharmaceuticals is headquartered at 10 EARLSFORT TERRACE, DUBLIN L2, D02.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.